Pixium Vision recently reported H119 financial results, with operating cash flows consistent with expectations. Importantly, the company announced improvements to the Prima Bionic Vision System (BVS), particularly with respect to the augmented reality (AR) glasses worn by patients, termed Prima 2. It plans to conduct feasibility testing on the second-generation system prior to commencing EU pivotal studies, which are now planned to start in H120 (vs H219 previously). This may de-risk the syst
06 Aug 2019
Pixium Vision - Refining Prima system before starting pivotal trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pixium Vision - Refining Prima system before starting pivotal trial
Pixium Vision recently reported H119 financial results, with operating cash flows consistent with expectations. Importantly, the company announced improvements to the Prima Bionic Vision System (BVS), particularly with respect to the augmented reality (AR) glasses worn by patients, termed Prima 2. It plans to conduct feasibility testing on the second-generation system prior to commencing EU pivotal studies, which are now planned to start in H120 (vs H219 previously). This may de-risk the syst